GoodRx (NASDAQ:GDRX) Shares Down 3% - Here's What Happened

GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) shares fell 3% during trading on Thursday . The stock traded as low as $4.78 and last traded at $4.90. 638,080 shares changed hands during trading, a decline of 55% from the average session volume of 1,414,575 shares. The stock had previously closed at $5.05.

Analyst Upgrades and Downgrades

Several research firms have recently commented on GDRX. Truist Financial cut their price target on GoodRx from $6.50 to $5.50 and set a "hold" rating for the company in a research note on Thursday, April 10th. The Goldman Sachs Group lowered their price target on GoodRx from $6.00 to $5.00 and set a "neutral" rating on the stock in a report on Friday, May 9th. Wells Fargo & Company dropped their target price on shares of GoodRx from $8.00 to $7.00 and set an "overweight" rating for the company in a report on Tuesday, April 29th. Finally, UBS Group cut their price target on GoodRx from $6.00 to $5.25 and set a "neutral" rating for the company in a report on Tuesday, May 13th. Five investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $6.55.

GoodRx Stock Performance

The stock's 50 day simple moving average is $4.34 and its two-hundred day simple moving average is $4.52. The company has a market cap of $1.70 billion, a PE ratio of 59.49, a P/E/G ratio of 2.25 and a beta of 1.24. The company has a quick ratio of 5.23, a current ratio of 5.23 and a debt-to-equity ratio of 0.74.

GoodRx (NASDAQ:GDRX - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $0.09 EPS for the quarter, topping the consensus estimate of $0.04 by $0.05. GoodRx had a return on equity of 7.85% and a net margin of 3.57%. The company had revenue of $202.97 million during the quarter, compared to analyst estimates of $202.25 million. During the same period in the prior year, the firm posted $0.08 earnings per share. The firm's revenue was up 2.6% on a year-over-year basis. As a group, research analysts anticipate that GoodRx Holdings, Inc. will post 0.13 earnings per share for the current year.

Insider Activity at GoodRx

In related news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the company's stock in a transaction on Thursday, July 3rd. The shares were sold at an average price of $4.80, for a total transaction of $51,249.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 4.53% of the company's stock.

Institutional Investors Weigh In On GoodRx

Hedge funds have recently modified their holdings of the stock. National Bank of Canada FI grew its position in GoodRx by 34.9% in the fourth quarter. National Bank of Canada FI now owns 8,308 shares of the company's stock valued at $39,000 after acquiring an additional 2,151 shares in the last quarter. Citizens Financial Group Inc. RI acquired a new stake in GoodRx during the 1st quarter valued at $44,000. Jump Financial LLC acquired a new stake in GoodRx during the 1st quarter valued at $49,000. RPO LLC purchased a new stake in GoodRx during the 4th quarter worth $52,000. Finally, Versor Investments LP acquired a new position in GoodRx in the 4th quarter worth $54,000. 63.77% of the stock is currently owned by hedge funds and other institutional investors.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.